Acarix AB (publ) (ACARIX.ST)
SEK 0.25
(-4.05%)
SEK 0.25
(-4.05%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 10.99 Million SEK | -37.71% |
| 2022 | 17.65 Million SEK | -2.22% |
| 2021 | 18.05 Million SEK | 131.14% |
| 2020 | 7.81 Million SEK | 22.46% |
| 2019 | 6.37 Million SEK | -12.86% |
| 2018 | 7.32 Million SEK | 43.05% |
| 2017 | 5.11 Million SEK | -71.2% |
| 2016 | 17.77 Million SEK | 416.12% |
| 2015 | 3.44 Million SEK | 8.92% |
| 2014 | 3.16 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 11.81 Million SEK | 6.04% |
| 2024 Q1 | 11.13 Million SEK | 1.27% |
| 2023 Q1 | 9.56 Million SEK | -45.83% |
| 2023 Q3 | 9.38 Million SEK | -28.89% |
| 2023 Q2 | 13.19 Million SEK | 38.0% |
| 2023 Q4 | 10.99 Million SEK | 17.19% |
| 2023 FY | 10.99 Million SEK | -37.71% |
| 2022 Q4 | 17.65 Million SEK | 156.0% |
| 2022 Q2 | 7.16 Million SEK | -40.21% |
| 2022 Q1 | 11.97 Million SEK | -33.68% |
| 2022 FY | 17.65 Million SEK | -2.22% |
| 2022 Q3 | 6.89 Million SEK | -3.69% |
| 2021 Q1 | 10.03 Million SEK | 28.41% |
| 2021 FY | 18.05 Million SEK | 131.14% |
| 2021 Q2 | 6.24 Million SEK | -37.76% |
| 2021 Q3 | 5.82 Million SEK | -6.74% |
| 2021 Q4 | 18.05 Million SEK | 210.15% |
| 2020 Q1 | 8.19 Million SEK | 28.53% |
| 2020 FY | 7.81 Million SEK | 22.46% |
| 2020 Q2 | 7.48 Million SEK | -8.72% |
| 2020 Q3 | 9.53 Million SEK | 27.35% |
| 2020 Q4 | 7.81 Million SEK | -18.04% |
| 2019 Q4 | 6.37 Million SEK | 5.77% |
| 2019 FY | 6.37 Million SEK | -12.86% |
| 2019 Q3 | 6.03 Million SEK | -22.33% |
| 2019 Q2 | 7.76 Million SEK | -5.39% |
| 2019 Q1 | 8.2 Million SEK | 12.12% |
| 2018 FY | 7.32 Million SEK | 43.05% |
| 2018 Q4 | 7.32 Million SEK | 55.94% |
| 2018 Q1 | 4.47 Million SEK | -12.59% |
| 2018 Q3 | 4.69 Million SEK | 36.45% |
| 2018 Q2 | 3.44 Million SEK | -23.09% |
| 2017 Q2 | 4.07 Million SEK | -26.23% |
| 2017 Q4 | 5.11 Million SEK | 86.89% |
| 2017 FY | 5.11 Million SEK | -71.2% |
| 2017 Q1 | 5.52 Million SEK | -68.89% |
| 2017 Q3 | 2.73 Million SEK | -32.88% |
| 2016 Q1 | - SEK | -100.0% |
| 2016 Q4 | 17.77 Million SEK | 12.01% |
| 2016 Q3 | 15.86 Million SEK | 0.0% |
| 2016 FY | 17.77 Million SEK | 416.12% |
| 2015 Q4 | 3.44 Million SEK | 0.0% |
| 2015 FY | 3.44 Million SEK | 8.92% |
| 2014 FY | 3.16 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ADDvise Group AB (publ) | 2.67 Billion SEK | 99.589% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 99.589% |
| Arcoma AB | 33.3 Million SEK | 66.978% |
| Bactiguard Holding AB (publ) | 329.7 Million SEK | 96.664% |
| BICO Group AB (publ) | 3.26 Billion SEK | 99.663% |
| Boule Diagnostics AB (publ) | 279.9 Million SEK | 96.071% |
| CellaVision AB (publ) | 212.32 Million SEK | 94.82% |
| Clinical Laserthermia Systems AB (publ) | 14.19 Million SEK | 22.533% |
| Chordate Medical Holding AB (publ) | 6.86 Million SEK | -60.112% |
| C-Rad AB (publ) | 122.4 Million SEK | 91.015% |
| Duearity AB (publ) | 17.53 Million SEK | 37.262% |
| Dignitana AB (publ) | 37.56 Million SEK | 70.724% |
| Episurf Medical AB (publ) | 19.8 Million SEK | 44.455% |
| Getinge AB (publ) | 24.69 Billion SEK | 99.955% |
| Scandinavian Real Heart AB (Publ) | 20.6 Million SEK | 46.612% |
| Iconovo AB (publ) | 14.55 Million SEK | 24.433% |
| Integrum AB (publ) | 22.07 Million SEK | 50.174% |
| Luxbright AB (publ) | 7 Million SEK | -57.112% |
| Mentice AB (publ) | 163.55 Million SEK | 93.276% |
| OssDsign AB (publ) | 105.25 Million SEK | 89.551% |
| Paxman AB (publ) | 44.5 Million SEK | 75.29% |
| Promimic AB (publ) | 16.15 Million SEK | 31.926% |
| Qlife Holding AB (publ) | 62.16 Million SEK | 82.31% |
| SciBase Holding AB (publ) | 21.27 Million SEK | 48.313% |
| ScandiDos AB (publ) | 37.18 Million SEK | 70.424% |
| Sectra AB (publ) | 1.64 Billion SEK | 99.33% |
| Sedana Medical AB (publ) | 44.06 Million SEK | 75.04% |
| Senzime AB (publ) | 58.06 Million SEK | 81.059% |
| SpectraCure AB (publ) | 14.97 Million SEK | 26.558% |
| Stille AB | 172.64 Million SEK | 93.63% |
| Vitrolife AB (publ) | 3.66 Billion SEK | 99.7% |
| Xvivo Perfusion AB (publ) | 250.56 Million SEK | 95.611% |